Arcturus Therapeutics (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed "significant and consistent" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.
The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.
The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.
Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.
Shares of Arcturus gained more than 2% in recent trading activity Monday.
Price: 13.61, Change: +0.28, Percent Change: +2.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.